BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 6, 2017--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Antony Mattessich, Chief Executive Officer, will present
at three upcoming investor conferences in September:
-
Morgan Stanley 15th Annual Global Healthcare Conference
Fireside
Chat: Monday, September 11, 2017 at 1:05 p.m. Eastern Time
Grand
Hyatt New York Hotel, New York, NY
-
Rodman & Renshaw 19th Annual Global Investment Conference
Presentation:
Tuesday, September 12, 2017 at 2:10 p.m. Eastern Time
Lotte New
York Palace Hotel, New York, NY
-
Cantor Fitzgerald 2017 Global Healthcare Conference
Presentation:
Monday, September 25, 2017 at 3:35 p.m. Eastern Time
InterContinental
New York Barclay Hotel, New York, NY
Live audio webcasts of the presentations can be accessed through the
Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on the
Company's website for two weeks following each presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral injection for the treatment of
moderate to severe glaucoma and ocular hypertension, as well as
sustained release intravitreal injections for the treatment of retinal
diseases. These injections include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
an extended release protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906006428/en/
Source: Ocular Therapeutix, Inc.
Investors
Burns McClellan
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular
Therapeutix
George Migausky
Interim Chief Financial Officer
gmigausky@ocutx.com
or
Media
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com
